Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Online Only Articles |

Methods for Staging Non-small Cell Lung CancerStaging Methods for NSCLC: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines FREE TO VIEW

Gerard A. Silvestri, MD, FCCP; Anne V. Gonzalez, MD; Michael A. Jantz, MD, FCCP; Mitchell L. Margolis, MD, FCCP; Michael K. Gould, MD, FCCP; Lynn T. Tanoue, MD, FCCP; Loren J. Harris, MD, FCCP; Frank C. Detterbeck, MD, FCCP
Author and Funding Information

From Medical University of South Carolina (Dr Silvestri), Charleston, SC; Montreal Chest Institute (Dr Gonzalez), McGill University Health Centre, Montreal, QC, Canada; the Division of Pulmonary, Critical Care, and Sleep Medicine (Dr Jantz), University of Florida, Gainesville, FL; the Pulmonary Section (Dr Margolis), Philadelphia VAMC, Philadelphia, PA; the Department of Research and Evaluation (Dr Gould), Kaiser Permanente Southern California, Pasadena, CA; the Section of Pulmonary and Critical Care Medicine (Dr Tanoue), and Yale University School of Medicine (Dr Detterbeck), New Haven, CT; and Maimonides Medical Center (Dr Harris), Brooklyn, NY.

Correspondence to: Gerard A. Silvestri, MD, FCCP, Medical University of South Carolina, 171 Ashley Ave, Room 812-CSB, Charleston, SC 29425; e-mail: silvestri@musc.edu

Funding/Sponsors: The overall process for the development of these guidelines, including matters pertaining to funding and conflicts of interest, are described in the methodology article.1 The development of this guideline was supported primarily by the American College of Chest Physicians. The lung cancer guidelines conference was supported in part by a grant from the Lung Cancer Research Foundation. The publication and dissemination of the guidelines was supported in part by a 2009 independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

COI Grids reflecting the conflicts of interest that were current as of the date of the conference and voting are posted in the online supplementary materials.

Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://dx.doi.org/10.1378/chest.1435S1.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

Chest. 2013;143(5_suppl):e211S-e250S. doi:10.1378/chest.12-2355
Text Size: A A A
Published online

Background:  Correctly staging lung cancer is important because the treatment options and prognosis differ significantly by stage. Several noninvasive imaging studies and invasive tests are available. Understanding the accuracy, advantages, and disadvantages of the available methods for staging non-small cell lung cancer is critical to decision-making.

Methods:  Test accuracies for the available staging studies were updated from the second iteration of the American College of Chest Physicians Lung Cancer Guidelines. Systematic searches of the MEDLINE database were performed up to June 2012 with the inclusion of selected meta-analyses, practice guidelines, and reviews. Study designs and results are summarized in evidence tables.

Results:  The sensitivity and specificity of CT scanning for identifying mediastinal lymph node metastasis were approximately 55% and 81%, respectively, confirming that CT scanning has limited ability either to rule in or exclude mediastinal metastasis. For PET scanning, estimates of sensitivity and specificity for identifying mediastinal metastasis were approximately 77% and 86%, respectively. These findings demonstrate that PET scanning is more accurate than CT scanning, but tissue biopsy is still required to confirm PET scan findings. The needle techniques endobronchial ultrasound-needle aspiration, endoscopic ultrasound-needle aspiration, and combined endobronchial ultrasound/endoscopic ultrasound-needle aspiration have sensitivities of approximately 89%, 89%, and 91%, respectively. In direct comparison with surgical staging, needle techniques have emerged as the best first diagnostic tools to obtain tissue. Based on randomized controlled trials, PET or PET-CT scanning is recommended for staging and to detect unsuspected metastatic disease and avoid noncurative resections.

Conclusions:  Since the last iteration of the staging guidelines, PET scanning has assumed a more prominent role both in its use prior to surgery and when evaluating for metastatic disease. Minimally invasive needle techniques to stage the mediastinum have become increasingly accepted and are the tests of first choice to confirm mediastinal disease in accessible lymph node stations. If negative, these needle techniques should be followed by surgical biopsy. All abnormal scans should be confirmed by tissue biopsy (by whatever method is available) to ensure accurate staging. Evidence suggests that more complete staging improves patient outcomes.

Figures in this Article